Inulin prebiotic ameliorates type 1 diabetes dictating regulatory T cell homing via CCR4 to pancreatic islets and butyrogenic gut microbiota in murine model

Autor(es):Mostrar menos -

Guimaraes, Jhefferson Barbosa ; Rodrigues, Vanessa Fernandes ; Pereira, Italo Sousa ; Manso, Gabriel Martins da Costa ; Elias-Oliveira, Jefferson ; Leite, Jefferson Antonio ; Waldetario, Mariana Camila Goncalves Miranda ; de Oliveira, Sarah ; Gomes, Arilson Bernardo dos Santos Pereira ; Faria, Ana Maria Caetano ; Ramos, Simone Gusmao ; Bonato, Vania L. D. ; Silva, Joao Santana ; Vinolo, Marco Aurelio Ramirez ; Sampaio, Ulliana Marques ; Clerici, Maria Teresa Pedrosa Silva ; Carlos, Daniela

• Tipo de documento: Artigo Científico
• Fonte: Journal of Leukocyte Biology; v. 115, n. 3, p. 14-pg., 2023-11-21.

Resumo

Gut dysbiosis is linked to type 1 diabetes mellitus (T1D). Inulin (INU), a prebiotic, modulates the gut microbiota, promoting beneficial bacteria that produce essential short-chain fatty acids for immune regulation. However, how INU affects T1D remains uncertain. Using a streptozotocin-induced (STZ) mouse model, we studied INU's protective effects. Remarkably, STZ + INU mice resisted T1D, with none developing the disease. They had lower blood glucose, reduced pancreatic inflammation, and normalized serum insulin compared with STZ + SD mice. STZ + INU mice also had enhanced mucus production, abundant Bifidobacterium, Clostridium cluster IV, Akkermansia muciniphila, and increased fecal butyrate. In cecal lymph nodes, we observed fewer CD4+Foxp3+ regulatory T cells expressing CCR4 and more Foxp3+CCR4+ cells in pancreatic islets, with higher CCL17 expression. This phenotype was absent in CCR4-deficient mice on INU. INU supplementation effectively protects against experimental T1D by recruiting CCR4+ regulatory T cells via CCL17 into the pancreas and altering the butyrate-producing microbiota. (AU)

• Processo FAPESP: 19/13858-0 - Efeito da administração do Bifidobacterium longum, com ou sem o prebiótico inulina, na produção de AGCC e na imunorregulação do DM1 em modelo experimental
• Beneficiário: Jhefferson Barbosa Guimarães
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 18/14815-0 - Estudo do perfil do microbioma intestinal e do potencial terapêutico de estratégias de intervenção na imunopatogenia do Diabetes tipo 1 e 2
• Beneficiário: Daniela Carlos Sartori
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores - Fase 2